Aktis Oncology has initiated a Phase 1b clinical trial for AKY-2519, a targeted radioconjugate aimed at treating metastatic castration-resistant prostate cancer (mCRPC) expressing B7-H3. This trial includes patients both new to and experienced with PLUVICTO® therapy, with preliminary results expected in 2027. The company also plans a second Phase 1b basket trial for other B7-H3 expressing solid tumors like lung and colorectal cancers later in 2026, aiming to broaden treatment options and gather robust clinical data. This development addresses unmet needs in prostate cancer treatment, especially for patients ineligible or unresponsive to current PSMA-targeted therapies.
LVMH is set to report Q3 earnings with an expected EPS of $2.47 and revenue of $22.02 billion, following strong Q2 sales of $22.20 billion driven by U.S. demand. The luxury goods company, which owns brands like Louis Vuitton and Dior, shows a P/E rat...
Sierra Bancorp reported Q2 earnings per share (EPS) of $0.77, below analyst expectations of $0.89, and revenue of $38.98 million, missing the forecast of $39.59 million. The EPS slightly declined from $0.78 a year ago, indicating a small year-over-ye...
Navitas Semiconductor, a maker of AI data center power chips, has seen its stock fall 40% this month, making its upcoming earnings report crucial. Analysts expect a loss of $0.04 per share and revenue near $10 million, reflecting a 31.3% decline from...
Michelin has published its financial report for the first half of 2026, which is now accessible on its official website. The report has also been officially filed with the French Autorité des Marchés Financiers (AMF), ensuring regulatory compliance. ...
Michelin has published and filed its half-year financial report as of June 30, 2026, with the French financial regulator AMF. The report and the presentation of the 2026 half-year results are accessible on Michelin's official website. This disclosure...
